First pill for rare bone disease enters human testing
Disease control
Recruiting now
This is the first study in people of an oral drug called ALE1 for hypophosphatasia (HPP), a rare genetic bone disorder. It aims to find out if the pill is safe, how the body processes it, and how it affects key biomarkers. The study will include about 120 healthy adults and adult…
Phase: PHASE1, PHASE2 • Sponsor: Alesta Therapeutics • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC